title: Endometrial integrin expression is independent of estrogen or progestin treatment in vitro.
abstract: OBJECTIVE
  To examine the regulation of endometrial integrin expression by estrogens and progestins in vitro.
  
  
  METHODS
  Immunocytochemical study.
  
  
  METHODS
  Academic research unit.
  
  
  METHODS
  Twenty-five regularly cycling women without endometrial pathology, of whom seven had endometriosis.
  
  
  METHODS
  Endometrial cells obtained by aspiration curettage were treated with diethylstilbestrol, promegestone, and antiprogestin. Immunocytochemistry was performed with antibodies directed against integrins alpha 1 beta 1, alpha 2 beta 1, alpha 4 beta 1, alpha 5 beta 1, alpha v beta 3, and beta 3 integrin subunit.
  
  
  METHODS
  Semiquantitative staining score.
  
  
  RESULTS
  Endometrial cells express several integrins in vitro in a consistent and cell specific pattern. Neither differences between treated and untreated cells nor an effect of treatment duration or dosage were observed. Cells from patients with and without endometriosis showed similar patterns.
  
  
  CONCLUSIONS
  The cellular distribution of integrin expression was similar to that described in vivo. In contrast, a steroid regulated expression could not be detected in vitro. Rather, a derepression by a factor not included in our model could be responsible for the cyclic appearance of some integrins. In endometriosis, no fundamental difference of integrin expression was detected.
authors.affiliation: Department of Obstetrics and Gynecology, Ruprecht-Karls-Universitaet, Heidelberg, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Sillem
authors.forename: S
authors.initials: S
authors.lastname: Prifti
authors.forename: M
authors.initials: M
authors.lastname: Schmidt
authors.forename: T
authors.initials: T
authors.lastname: Rabe
authors.forename: B
authors.initials: B
authors.lastname: Runnebaum
mesh_terms: D002478:Cells, Cultured; D004054:Diethylstilbestrol / Q000494:pharmacology; D004715:Endometriosis / Q000378:metabolism*; D004717:Endometrium / Q000187:drug effects / Q000378:metabolism*; D004967:Estrogens / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D039222:Integrin alpha1beta1; D039041:Integrin alpha4beta1; D016023:Integrins / Q000032:analysis / Q000378:metabolism*; D011372:Progestins / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D011397:Promegestone / Q000494:pharmacology; D038981:Receptors, Collagen; D017469:Receptors, Fibronectin / Q000032:analysis; D016201:Receptors, Lymphocyte Homing / Q000032:analysis; D019030:Receptors, Vitronectin / Q000032:analysis
chemical_list: D004967:Estrogens; D039222:Integrin alpha1beta1; D039041:Integrin alpha4beta1; D016023:Integrins; D011372:Progestins; D038981:Receptors, Collagen; D017469:Receptors, Fibronectin; D016201:Receptors, Lymphocyte Homing; D019030:Receptors, Vitronectin; D004054:Diethylstilbestrol; D011397:Promegestone